Find information on thousands of medical conditions and prescription drugs.

Chlortetracycline

Chlortetracycline (Aureomycin®, Lederle) is the first tetracycline antibiotic to be discovered. It was discovered in 1945 by Dr Benjamin Duggar in a soil sample from Sanborn fields, yielding an actinomycete, Streptomyces aureofaciens (hence the name Aureomycin).

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Productivity and Economic Effects of Antibiotics Used for Growth Promotion in U.S. Pork Production
From Journal of Agricultural and Applied Economics, 12/1/03 by Miller, Gay Y

Public health experts are concerned about the diminishing efficacy of antibiotics. Some have called for a ban on growth-promoting antibiotics in animal agriculture. This study identifies the contribution of growth-promoting antibiotics in the grower/finisher phase of U.S. pork production. With National Animal Health Monitoring System swine data, relationships are estimated between growth-promoting antibiotic use and productivity. Results indicate improvements in average daily gain (0.5%), feed conversion ratio (1.1%), and mortality rate (reduced 0.22 percentage points); these productivity improvements translate into a profitability gain of $0.59 per pig marketed, or an improvement of 9% in net profits associated with growth promotion antibiotics.

Key Words: antibiotics, economics, growth promotants, productivity, resistance, swine

JEL Classifications: Q12, Q18

Since the early 1950s, antibiotics have been used at subtherapeutic1 levels to promote the growth and overall health of livestock (Zimmerman). There has been concern for many years, and there is now a growing concern among health officials, physicians, veterinarians, and the public at large, regarding the diminishing efficacy of antibiotics in human and veterinary medicine (Levy; Mazel and Davies; McEwen and Fedorka-Cray; World Health Organization Director-General). Many fear that the practice of administering antibiotics at subtherapeutic levels over the course of an animal's production cycle contributes to the accelerated development of antibiotic resistance in bacteria (Levy; Teuber). Resistant bacteria can cause an antibiotic-resistant disease directly or they can pass the genetic material associated with resistance to other bacteria (Mazel and Davies), thus increasing the problems in disease treatment for both humans and animals. Resistant Salmonella that could cause food-associated illness in people have been documented in pork (Farrington et al.), and salmonellosis is a costly condition in humans (Buzby et al.).

A recent report issued by the Union for Concerned Scientists (Mellon, Benbrook, and Benbrook) emphasizes the significant information gaps that still exist regarding the use of antimicrobials on farms in the United States and their effect on human health through the development of antimicrobial-resistant bacteria. A thorough economic analysis of the benefits and costs of subtherapeutic animal antibiotics to society is needed, accounting for today's food animal genetics and production practices, so that the science base for the debate includes an economics contribution. Understanding the economic value of growth-promoting antibiotic use to the individual pork producer is a critical first step when considering policies to reduce or eliminate the availability of this input to the pork industry. In this study, we attempted to estimate the implicit value of antibiotics used for growth promotion to swine producers using national data and to identify gaps in the knowledge base. The results obtained from this effort will assist policy makers in the design of a balanced, science-based response to this critical issue.

Previously Reported Benefits of Antibiotics in Pork Production

Growth-promoting antibiotics are widely used in U.S. pork production. A 1995 survey conducted by the National Animal Health Monitoring System (NAHMS) determined that over 91% of the operations surveyed reported using antibiotics as a disease preventive or growth promotant in feed (USDA/APHIS 1995). The extensive use of growth-promoting antibiotics by U.S. pork producers is summarized in Dewey et al. Using the NAHMS 1990 survey results, they described the use of in-feed antimicrobials across different stages of production. Of the 712 producers surveyed, 88% reported using antimicrobials in feeds. The production phases with the highest use were nursing piglets fed creep feed and nursery piglets fed starter rations. Of the feeds used for grower/finisher (G/F) pigs, 62-73% contained antimicrobials, with the majority being fed on a continuous basis. The antibiotics most commonly fed to G/F pigs were tetracyclines, bacitracin, tylosin, and carbadox. The antibiotics most commonly used for growth promotion (as a percentage of operations reporting) by producers surveyed for the 1995 NAHMS survey were bacitracin (52.1 %), chlortetracycline (41.1%), and tylosin (30.4%). Approximately 78% of the operations surveyed reported using at least one of these antibiotics during the G/F phase of production (USDA/APHIS 1996).

Pork production is complex and multidimensional, complicating farm-level economic analyses considerably. The traditional approach to evaluating the economic importance of inputs to a production process is to estimate the production function using econometric methods (Dillon and Anderson; Heady and Dillon). In a recent study, Losinger analyzed data from the 1995 NAHMS Swine Study to identify the effect of different management practices on the feed conversion ratio (FCR) for finisher pigs. Using a forward-stepwise variable selection approach, Losinger found that improvements in FCR were associated with not administering chlortetracycline (the most commonly used growth-promoting antibiotic) through feed or water as a disease preventive or growth promotant. Losinger suggested one possible explanation for this finding was the ineffectiveness of low doses of chlortetracycline in the presence of certain pathogens that have limited susceptibility to this class of antibiotic. The other management practices identified by Losinger as being associated with improvements in FCR were the use of more than three different feed rations in the G/F phase and the practice of mixing rations off-farm. In a related study, Losinger et al. (1998a) used the 1995 NAHMS survey to examine the factors associated with mortality rate (MR) among G/F pigs. Using a step-wise logistic procedure, their results suggest that the use of antibiotics as a disease preventive or growth promotant significantly increased the odds of MR above the median (2.3%).

The benefits associated with the use of growth-promoting antibiotics in swine production are thought to include improvements in average daily gain (ADG), FCR, farrowing rate, baby pig survival, and MR. A number of studies have estimated the economic effect for pork producers of eliminating antibiotic use (Beran; Cromwell 2000; Gilliam and Martin; Hayes et al.; Mann and Paulsen). Cromwell (2000) estimates the net economic benefit of growth-promoting antibiotic use from post-weaning through the G/F phase of production to be $2.99 per market hog. Of this total, he estimates that savings from improvements in FCR and ADG represented 47 and 42% of the benefits from antibiotics, respectively. Reported improvements in ADG and FCR vary widely among studies, in part because of differences between studies in the age of pigs, animal genetics, the cleanliness of study operations, and variation in facility management practices. After analyzing data from 1,194 studies on the efficacy of antibiotics in U.S. pig production, Cromwell (1991) observed that the effect of antibiotics on ADG and FCR was greatest for young pigs and declined as pigs approach market weight. He noted that overall antibiotic effectiveness did not appear to diminish over the 36-year period (1950-1986) in which these studies were conducted. His findings confirmed that antibiotic response was significantly greater for pigs raised in actual farm conditions as compared to pigs raised on experimental research facilities and on university farms, where the conditions tend to be cleaner and pigs are less subject to disease. Beran estimated that the cost of adding antibiotics to feed rations was approximately 3.75% of the total ration costs and that producers realize a $2.00 return through improved FCR for each dollar spent on growthpromoting antibiotics. Gilliam and Martin assumed that without antibiotics, ADG for pigs between 15 and 40 pounds would decline by approximately 23% while FCR would decrease by roughly 6.5%. For G/F hogs weighing more than 40 pounds, ADG and FCR were predicted to decline by 5.5 and 2%, respectively. Assuming that producers maintained output at preban levels by feeding additional animals, their analysis suggested that production costs for hog producers would increase by $533 million ($6.94 per head), which is based on output, price, and cost conditions in 1973. In Mann and Paul sen's study, ADG and FCR following a ban on antibiotics were expected to fall by 10.7 and 3.8%, respectively. Their findings suggest that because of decreased production following a ban, the increase in hog prices will more than offset the rise in production costs, resulting in a 4.5% increase in profits to pork producers resulting from increased farm prices in the short run. In the long run, they predict little change in pork producer profitability. A recent study by Hayes et al. suggested that the most likely scenario following a ban would be a decline in ADG of 1.3% for pigs weighing 50-100 pounds and 1.8% for pigs above 100 pounds. For these same weight categories, FCR was expected to decline by 1.7 and 1.5%, respectively. Expected increases in MR following the ban were 1.5 percentage points for baby piglets and 0.04 percentage points (there is some uncertainty if this is percentage points or percentages) for G/F hogs (Hayes et al.). On the basis of the results from their "most likely" scenario, a ban on antibiotics used for growth promotion would increase production costs by $6.05 per head initially and $5.24 per head after 10 years. Profit would decline initially by $4.17 per head and by $0.79 per head after 10 years.

Other authors have approached the problem from a societal welfare perspective (Manchanda, Kliebenstein, and McKean; Wade and Barkley). In their study, Wade and Barkley first estimate the supply and demand for pork. Then using these estimated curves, they conduct a welfare analysis of the possible implications in welfare from a ban of antibiotics if pork supply decreases by as much as 8%, and pork demand increases by as much as a 10%. Their analysis shows that the welfare effects can be either positive or negative for both consumers and producers depending on how much demand expands and how much production declines. At one extreme, producer and consumer surplus each expands in excess of $200 million (when the pork supply declines very little, but demand increases by 10%); at the other extreme, consumer surplus declines by $199 million and producer surplus declines by $224 million (when pork supply declines by 8% with no corresponding increase in demand). Manchanda, Kliebenstein, and McKean use the Food & Agricultural Policy Research Institute (FAPRI) model in conjunction with a report from Rachelle Laboratories that documents productivity differences between different antibiotics used for growth promotion. Combining these materials with varying assumptions about the possible expansion in the demand for pork that might be associated with a perceived safer product (e.g., less chance of antibiotic residues), they estimated retail pork price shifts as small as $0.05/lb higher (with no change in demand) up to an increase of $0.09/lb (with a 5% expansion in demand). They also estimated farm prices would rise by $2.14/cwt (with no change in demand) and as much as $3.96/cwt (with an increase in pork demand of 1 %) from a complete ban in antibiotics.

The pork industry has changed dramatically in the last few decades (Rhodes). The industry is more concentrated, with fewer and larger producers. Pig genetics and production practices have changed. Thus, it is likely that the productivity and economic effect of feedgrade antibiotics has changed since the mid1970s, when much of the work was done (Gilliam and Martin; Mann and Paulsen) with productivity estimates for U.S. production systems on the economics and productivity effects of antibiotics. One criticism of the Hayes et al. study is that their biological assumptions are derived from European pork producers, and these assumptions could be quite inappropriate for the U.S. pork production system. Considering the dated nature of many studies, the wide variability in published results, the growing concerns of the development of resistance, the amount of antimicrobial usage, and the potential for resistance development, further study on this important topic is warranted. Thus, the primary objectives of our study were (1) to use U.S. industry-level data to identify the relationships between antibiotics used for growth promotion and other animal health and management practices on production performance (specifically, ADG, FCR, and MR) in the G/F phase of hog production, (2) to estimate the associated economic effect for pork producers at the farm level, and (3) to identify where knowledge gaps exist in this overall topic and to suggest future research needs.

Material and Methods

The 1990 and 1995 NAHMS Swine Survey data were used. These surveys were designed to provide statistically valid estimates of key parameters related to the health, management, and productivity of the U.S. swine herd. Data collection for each survey was conducted in two phases. In the first phase, operations were identified and contacted by a National Agricultural Statistics Service (NASS) enumerator, who asked producers to fill out the General Swine Farm Management Report (GSFMR) survey. The GSFMR survey asked general questions about herd management and production. In the second phase, a subset of operations from the first phase were selected and visited by a NAHMS-trained Veterinary Medical Officer. These visits involved a more detailed inquiry into the specific practices and experiences of the operation. In 1990, sampling occurred in 18 states, representing 84% of the U.S. swine operations and 95% of the nation's hog population (USDA/APHIS 1992). In 1995, sampling occurred in 16 states, accounting for approximately 75% of the pork producers and 91% of the U.S. hog inventory (USDA/APHIS 1995, 1996).

To improve sample size and, hence, power of our analysis, observations from the 1990 and 1995 surveys were combined. Data definitions and details on additional methods are outlined in the Appendix.

Linear regression was used to identify relationships between productivity in the G/F unit, antibiotic use, and other potentially relevant factors of production. Salient predictors for ADG, FCR, and MR were retained if p

The backward-stepwise MLE was chosen because it provides reasonably consistent and efficient estimators. We chose the set of possible explanatory variables (Tables 1 and 2) from among those available in the NAHMS dataset on the basis of our review of the literature on the productivity effects of antibiotic use, the basic animal production literature, and what we believed is generally common knowledge about pig growth among production-focused veterinarians and producers. Thus, we proceeded without a specific theory as to the exact specification of the regression model. Under such circumstances, using the backward-stepwise MLE seemed an appropriate choice.

To evaluate the effect of antibiotic-related variables as a group on the estimated models, a joint hypothesis test was performed with exclusion restrictions imposed on the relevant variables. The test compares the significance of two models: one with the antibiotic variables included and one without. With the use of the sum of squared residuals generated by the unrestricted and restricted models, the joint significance of these variables was evaluated by computing the F-statistic, determining its sampling distribution, and calculating the p-value to determine the significance level.

With the results from the regression models, we then estimated the effect of growth-promoting antibiotics on the performance of G/F pigs in terms of percentage. Predictions were generated for an independent, mediumsized (between 800 and 3,000 head entering the G/F unit in the last 6 months), Midwestern farrow-to-finish producer in 1995. We then express these performance figures in economic terms with a swine enterprise budgeting model developed by Miller, Song, and Bahnson. This budgeting model estimated the profitability of batch finishing of pigs for a barn designed to place any number of feeder pigs and was well suited to evaluating the effects of antibiotics on productivity and mortality. Default values for market hog weight and price, fixed and variable costs of production, and other variables used by this model reflected 1995-1998 U.S. averages. We upgraded these default values to reflect 1996-1999 U.S. averages for important costs. Upgraded cost assumptions included: feeder pig price, $40.85/head; corn, $2.76/bushel; soybean meal, $199.40/ton; and base market hog price, $41.88/live cwt. We express profitability differences between using and not using antibiotics for growth promotion on a per-pig marketed basis.

Results and Discussion

ADG and FCR Models

Summary statistics for ADG, FCR, and MR by NAHMS survey year demonstrate no differences in ADG or FCR between 1990 and 1995 (Table 3). Although FCR appears to be better (lower) in 1990, the difference in FCR values across the two survey years is not significant (p > .10). Mean ADG (1.626 and 1.631) of finishers was comparable to that reported by PigCHAMP® (1.61) (Regents of the University of Minnesota) for 1999. Mean FCR (3.179 and 3.268) also was comparable to PigCHAMP reports (3.12). MR (2.28) was lower than that reported by PigCHAMP (2.80).

The estimated models for ADG and FCR are presented in Table 4. An increase in the number of days that antibiotics were fed during the G/F phase was associated with improvements in both ADG and FCR. In the case of FCR, however, using more than one antibiotic was associated with poorer (higher) feed conversion. Improvements in ADG and FCR were also associated with the feeding of multiple rations during the G/F phase. There did appear to be a substitution effect between multiple rations and antibiotic use; increasing the number of rations was associated with poorer ADG and FCR when antibiotics were used for growth promotion (negative estimated coefficients for Dabx1rat, Dabxrat2, and Dabx3rat in the ADG model and a positive coefficient for Dabx1rat in the FCR model). The interaction between antibiotic use and the number of diseases diagnosed in the G/F unit also was associated with poorer ADG; this effect might be capturing the response of producers who use antibiotics for growth promotion when there is an increase in the prevalence of disease, or the positive effects of antibiotics used for growth promotion are simply overwhelmed by the negative influence of diseases. When interpreting these results, it is important to emphasize that this study focuses on antibiotic use for growth promotion and not antibiotic use for disease treatment. Being a medium- or large-sized operation was associated with better (lower) FCR. Independent producers who marketed through a cooperative were associated with poorer (higher) FCR. Higher MR was associated with poorer ADG and FCR.

Testing the joint significance of the antibiotic variables for the ADG and FCR models, the F-tests suggest that when the ADG and FCR models are evaluated together, the antibiotic variables were jointly significant (p = .026). When ADG and FCR were evaluated separately, the only model in which the antibiotic variables were jointly significant was the ADG model (p = .058). The F-test for joint significance for the FCR model alone was not significant (p = .123).

MR Model

Variables explaining MR (Table 5) suggest that antibiotics fed over a longer period of time (abxdays) were associated with reduced MR. Using two antibiotics for growth promotion in the presence of disease in the G/F unit (Dabx2dia) was associated with an increase in MR, whereas vaccination against disease (vacc) was associated with lower MR. The interpretation of the use of two antibiotics in the presence of disease is uncertain. It is likely simply that more disease is associated with higher mortality; it is also possible that producer response to more disease is to try to decrease the effect by using a second antibiotic for growth promotion. Weaning piglets at an older age (weanage) was also associated with a lower MR. The average age at weaning was 26.4 days, with a standard deviation of 9.2 days. As cull rate (pcull) increased, MR increased.

In terms of the added explanatory variables, the only apparent relationship is the positive coefficient associated with Dfac4, which implies that higher MR was associated with pasture-raised pigs. The magnitude of this estimated coefficient was also large. Among the biosecurity measures evaluated, it appeared that the practice of restricting entry only to employees (Drestrcf) was associated with a lower MR, whereas purchasing pigs from off-site sources (Doffsite) was associated with increased MR.

Testing the joint significance of the antibiotic variables for the MR model revealed that these variables were not jointly significant (p = .223).

Predicting the Effect of Antibiotic Use on Productivity, Mortality, and Profit

The values and assumptions used for the key parameters in the models are presented in Table 6. These data reflect the typical (mean or mode) values for commercial swine farms in the NAHMS data. It was also assumed that no pigs were purchased from off-site sources, and access to facilities was restricted to employees only. Given these assumptions, and combining with the estimated coefficients from the associated models (Tables 4 and 5), it was estimated that antibiotics were associated with improved ADG and FCR of 0.5 and 1.1%, respectively, and with better MR (Table 7).

Important basic economic summary values were calculated, including total revenue per year, total costs per year, return above total costs, return above operating costs, and net present value. Combined with the improvements to ADG, FCR, and MR (Table 7), the estimated increase in annual returns above total costs from antibiotics for a 1,020-head finishing barn was $1,612, or $0.59 per pig marketed. The economic significance of this number is revealed when compared to the estimated net returns to pig finishing operations as reported by the Illinois Farm Business Farm Management Association, which in 2000 is estimated to be $3.09/cwt or $6.52/pig. These values suggest that the economic benefit generated by using antibiotics in the G/F unit represents approximately 9% of the net return realized by Illinois pig finishing operations in 2000.

Input Substitution

An interesting result from the ADG and FCR models is the relationship implied by the productivity influence of growth-promoting antibiotics and the number of rations used during the G/F phase. Increasing the number of rations was associated with improved ADG and FCR when considered alone (rations), but the interaction term Dabxlrat carried the opposite sign on the estimated coefficient. Figure 1 shows the implied association of increasing the number of different rations fed during the G/F phase on ADG and FCR when antibiotics are and when they are not used. In both cases, improvements in productivity from the use of multiple rations were associated with no use of antibiotics. The economic implications of using multiple rations indicate that when five rations are used, the associated net economic benefit for the use of growth-promoting antibiotics is negative (Figure 2).

Tailoring rations more specifically to meet the dietary needs of pigs throughout the GfF phase (the number of different rations is a good proxy for this) might serve as a substitute for antibiotics used for growth promotion. Our results imply that antibiotics used for growth promotion are of value mainly when four or fewer different rations are used in finishing. Producers managing finishing operations where diets are tailored to meet pig growth needs over time might not see the same benefits from using antibiotics as those who feed a small number of different diets.

It is also possible that a positive association exists between the number of rations used and the level of management, with better managed operations tending to use more rations. In this study, we see improved productivity as the number of rations increase when no antibiotics are used. We also see improved ADG as more rations are used when one antibiotic is used, but a decrease in ADG with increasing number of rations when more than one antibiotic is used, and we see no change in FCR by increasing the number of rations with one antibiotic used for growth promotion. Therefore, if number of rations used is in some way a proxy for management, then it appears mainly to have a positive effect on productivity in the absence of antibiotics; antibiotic use substitutes (up to some point) for increased number of rations (perhaps a proxy for better management).

Knowledge Gaps and Further Research

These econometric results face several limitations, and care is needed to interpret the results. First, although this study uses the best available national survey data on U.S. hog production, improved data sources would allow additional hypotheses to be explored. For example, it is possible that there would be increased variability in ADG and FCR when antibiotics are not used for growth promotion. With increased variability in ADG and FCR, pigs would likely be marketed at a wider range of sizes, and this would contribute to increased revenue variability given the pricing structure for pigs. Additional survey information concerning size variation at marketing could then be combined with information on market premiums by size to determine whether this effect is economically significant.

Second, productivity effects of antibiotic use in gestation and farrowing phases of production are poorly understood, but it is believed that antibiotics increase litter size. Additionally, implications in preweaning and nursery phases of production, where antibiotic use can influence growth, growth efficiency, and mortality are not well documented (Tubbs et al.). A better understanding in these other production phases is needed to begin to assess the true economic implications for the swine industry.

Third, the economic value of growth-promoting antibiotics in their role in disease prevention could be significant. Our econometric framework applied in this study might not capture the entire value that pig finishing producers could realize from antibiotic use for growth promotion in their role of reducing the risk of a significant decline in herd health status. Mean values fail to capture downside risks associated with variance around the mean. Additional studies, such as surveys of producer willingness-to-pay to reduce herd health risks might be conducted to help in providing derived estimates of growth-promoting antibiotic input valuation.

Fourth, the estimated economic value assumes that, on average, we expect to see the productivity gains predicted by the models. However, the joint significance testing on the antibiotic use variables suggests that perhaps this will not be the case. If only this hypothesis testing were considered, with no effects on MR, the economic gain from growth-promoting antibiotic use would be even smaller than estimated here.

Other effects that could markedly influence the economic implications of antibiotic use, but where virtually no evidence exists, are the influence on leanness, the interaction between antibiotic use and pig genetic makeup, or the interaction with a host of environmental pressures that can influence pig diseases and productivity. Additionally, the influence of management (or animal husbandry) affects efficiency of production and the economics of pig production. It is hoped that future NAHMS datasets will include additional environmental factors on farms, as well as information on pig genetics, in order to facilitate estimation of some of these interactions.

Further statistical analyses focusing on the risk-reducing effects of antibiotics used for growth promotion are needed but are beyond the scope of the current investigation. Examination of the influence of antibiotics on variability of productivity parameters is a possible approach to capturing these risk-reducing aspects if they exist. The price differential associated with under- and overweight pigs is an important influence of revenues and profits; if antibiotic use decreases variability of growth, it will decrease even further the variability of revenue and profit. This occurs because many producers have production contracts that are time sensitive for either delivery of finished pigs to packers or arrival of young pigs for placement in the barns, thus requiring empty barns on specific dates rather than removal on the basis of pig size (Miller, Song, and Bahnson).

We do have some measurements that might capture "good management"; at least some of the variables would be included in a set of good production practices (e.g., number of rations, hygiene and biosecurity measures such as all in-all out management, and quarantining pigs on arrival). The latter two of these variables were not significant and, therefore, not retained in the final model. But an open question that remains is whether better managed herds might be more likely to survive in the face of reduced availability of antibiotics for growth promotion. Although the answer to this question is not simple, it is our opinion that better managed farms carry a number of attributes that could increase the likelihood of surviving all types of changes, including the elimination of the use of antibiotics for growth promotion.

Summary

Our results suggest that the economic effect of the use of antibiotics for growth promotion in G/F units in the United States is sufficiently high ($0.59/pig marketed, or an improved profitability of 9%) that pork producers might be reluctant to produce pigs without this input. However, we also found a potential for substantial substitutability with this input and other production inputs that could help overcome the negative influence of removing antibiotics. The potential trade-off in applying some alternative inputs might be the added complexity associated with the use of these inputs. This is particularly important if the added complexity is such that the alternatives are excluded or limited to smaller production units.

The widespread use of antibiotics for growth promotion within the U.S. pork industry suggests that most producers believe their profits are higher with use than they would be otherwise or that antibiotics are a low-cost risk-reducing measure. Further research is needed to determine the degree of the latter possibility. There is a need for additional economic research as well as controlled feeding trials that will carefully quantify the relationships between growth-promoting antibiotic use and productivity measures carried out in field situations reflective of current U.S. production systems; such studies should reflect current pig genetics, size of operations, typical diseases, and other environmental pressures, among other factors. Additionally, the risk to human health from the use of antibiotics in growth promotion in swine production needs to be assessed. Combining a risk analysis framework with an integrated bioeconomic model for consumers would provide important and substantial input to the current debate on growth-promoting antibiotic use in food animal production.

1 Although a precise definition is still the subject of debate, antibiotic use is generally classified as subtherapeutic if it is used to improve animal performance (e.g., for growth promotion) and therapeutic if used to treat specific health problems (National Research Council). Subtherapeutic use typically involves lower dosages and longer periods of use, whereas therapeutic use typically involves higher dosages for a relatively short period of time.

[Received August 2002; Accepted January 2003. J

References

Beran, G.W. "Use of Drugs in Animals: An Epidemiologic Perspective." Proceedings of the Symposium on Animal Drug Use-Dollars and Sense. G.E. Stefan, ed., pp. 3-27. Rockville, MD: Center for Veterinary Medicine, 1988.

Buzby, J.C., T. Roberts, C.-T.J. Lin, and J.M. MacDonald. Bacterial Foodborne Disease Medical Costs and Productivity Losses. U.S. Department of Agriculture/Economic Research Service Pub. No. AER 741, August 1996.

Cromwell, G.L. "Antimicrobial Agents." Swine Nutrition. E.R. Miller, D.E. Ullrey, and A.J. Lewis, eds., pp. 297-314. Stoneham, MA: Butterworth-Heinemann, 1991.

_____. "Why and How Antibiotics are Used in Swine Production." Animal Biotechnology 13(2002):7-27.

de Lange, C.EM., and S.K. Baidoo. "Feeding for Profit in the Finisher Barn." Staying Competitive: Tomorrow's Technology for Today, C.EM. de Lange, ed. Volume 11. Manitoba Swine Seminar, 1997. Manitoba: Manitoba Agriculture and Food. Internet site: http://www.gov.mb.ca/ agriculture/livestock/pork/swine/bab10s14.html (Accessed August 2003).

Dewey, C.E., B.D. Cox, B.E. Straw, E.J. Bush, and S. Hurd. "Use of Antimicrobials in Swine Feeds in the United States." Journal of Swine Health and Production 7(1999):19-25.

Dillon, J.L., and J.R. Anderson. The Analysis of Response in Crop and Livestock Production. New York: Pergamon Press, 1990.

Farrington, L.A., R.B. Harvey, S.A. Buckley, L.H. Stanker, and P.D. Inskip. "A Preliminary Survey of Antibiotic Resistance of Salmonella in Market-Age Swine." Mechanisms in the Pathogenesis of Enteric Diseases 2. P.S. Paul and D.H. Francis, eds., Chapter 31:291-97. New York: Klewer Academic/Plenum Publishers, 1999.

Gilliam, H.C., and J.R. Martin. "Economic Importance of Antibiotics in Feeds to Producers and Consumers of Pork, Beef and Veal." Journal of Animal Science 40,6(1975):1241-55.

Hayes, D.J., H.H. Jensen, L. Backstrom, and J. Fabiosa. "Economic Impact of a Ban on the Use of Over-the-Counter Antibiotics in U.S. Swine Rations." Staff Report 99 SR 90, Center for Agricultural and Rural Development, Iowa State University, December 1999.

Heady, E.O., and J.L. Dillon. Agricultural Production Functions. Ames, IA: Iowa State University Press, 1961.

Illinois Farm Business Farm Management Association. 2000 Livestock Report. Urbana-Champaign, IL: Department of Agricultural and Consumer Economics, University of Illinois at Urbana-Champaign, March 2001.

Levy, S.B. "Antibiotic Use for Growth Promotion in Animals: Ecologie and Public Health Consequences." Journal of Food Protection 50(1987):616-20.

Losinger, W.C. "Feed-conversion Ratio of Finisher Pigs in the USA." Preventive Veterinary Medicine 36(1998): 287-305.

Losinger, W.C., E.J. Bush, M.A. Smith, and B.A. Corso. "An Analysis of Mortality in the Grower/Finisher Phase of Swine Production in the United States." Preventive Veterinary Medicine 33(1998a): 121-45.

Losinger, W.C., E.J. Bush, G.W. Hill, M.A. Smith. L.P. Garber, J.M. Rodriguez, and G. Kane. "Design and Implementation of the United States National Animal Health Monitoring System 1995 National Swine Survey." Preventive Veterinary Medicine 34(1998b): 147-59.

Manchanda, S., J.B. Kliebenstein, and J.D. McKean. "Economic Comparison of Alternatives to Sulfamethazine Use in Pork Production." Staff Papers Series #266. Ames, IA: Department of Economics, Iowa State University, july 1995.

Mann, T., and A. Paulsen. "Economic Impact of Restricting Feed Additives in Livestock and Poultry Production." American Journal of Agricultural Economics 58(February 1976):47-53.

Mazel, D., and I. Davies. "Antibiotic Resistance in Microbes." Cellular and Molecular Life Sciences 56(1999):742-54.

McEwen, S.A., and PJ. Fedorka-Cray. "Antimicrobial Use and Resistance in Animals." Clinical Infectious Diseases 34(Suppl. 3, 2002):S93S106.

Mellon, M., C. Benbrook, and K.L. Benbrook. Hogging It: Estimates of Antimicrobial Abuse in Livestock. Cambridge, MA: Union of Concerned Scientists, January 2001.

Miller, G.Y., Y. Song, and RB. Bahnson. "An Economic Model for Estimating Batch Finishing System Profitability with an Application in Preventing Porcine Respiratory Disease Complex." Journal of Swine Health and Production 9,4(2001): 169-77.

National Research Council. The Use of Drugs in Food Animals: Benefits and Risks. Washington, DC: National Academy Press, 1999.

Regents of the University of Minnesota. "Benchmarking in Swine Herds." St. Paul, MN: PigCHAMP® 1999, p. 23.

Rhodes, V.J. "The Industrialization of Hog Production." Review of Agricultural Economics 17(1995): 107-18.

StataCorp. Stata Statistical Software: Release 6.0. College Station, TX: Stata Corporation, 1999.

Teuber, M. "Spread of Antibiotic Resistance with Food-borne Pathogens." Cellular and Molecular Life Sciences 56(1999):755-63.

Tubbs, R.C., H.S. Kurd, D.A. Dargatz, and G.W. Hill. "Preweaning Morbidity and Mortality in the United States Swine Herd." Journal of Swine Health and Production 1,1 (1993):21-28.

United States Department of Agriculture, APHIS (USDA/APHIS). National Swine Survey: Morbidity/Mortality and Health Management of Swine in the United States. Fort Collins, CO: USDA/APHIS/VS Publication N101.0192, 1992.

_____. Swine '95 Part I: Reference of 1995 Swine Management Practices. Fort Collins, CO: USDA/APHIS/VS Publication N 186.995, 1995.

_____. Swine '95 Part II: Reference of 1995 U.S. Grower/Finisher Health and Management Practices. Fort Collins, CO: USDA/APHIS/VS Publication N201.696, 1996.

Wade, M.A., and A.P. Barkley. "The Economic Impacts of a Ban on Subtherapeutic Antibiotics in Swine Production." Agribusiness 8,2(1992):93107.

World Health Organization Director-General. Overcoming Antimicrobial Resistance. World Health Report on Infectious Diseases 2000. Internet site: http://www.who.int/infectious-disease-report/ 2000/other_versions/index-rpt2000_text.html (Accessed 2002).

Zimmerman, D.R. "Role of Subtherapeutic Levels of Antimicrobials in Pig Production." Journal of Animal Science 62(Suppl. 3, 1986):6-17.

Gay Y. Miller is professor, Department of Veterinary Pathobiology, Department of Veterinary Clinical Medicine, and Department of Agricultural and Consumer Economics, University of Illinois, Urbana, IL. Kenneth A. Algozin was postdoctoral associate, Department of Veterinary Pathobiology, University of Illinois at Urbana-Champaign, IL, and is now Shiawassee River program manager for The Nature Conservancy-Michigan Chapter, Owosso, MI. Paul E. McNamara is assistant professor, Department of Agricultural and Consumer Economics, University of Illinois, Urbana, IL. Eric J. Bush is Veterinary Epidemiologist, USDA/ APHIS/VS, Centers for Epidemiology and Animal Health, Fort Collins, CO.

This study was funded in part by a grant from the Illinois Council on Food and Agricultural Research (C-FAR). The authors recognize the contributions of Stephen Ott for his helpful comments and the USDA/ APHIS/VS staff in Ft. Collins, CO, for their assistance with the NAHMS data.

Copyright Southern Journal of Agricultural Economics Dec 2003
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Chlortetracycline
Home Contact Resources Exchange Links ebay